

Appendix C

Amended Claims

E1 28. (Amended) A process for treating septicemia caused by gram-negative bacteria, by gram-positive bacteria, by trauma or by injury, which comprises administering to a patient in need therefor an agent an effective amount of lipopolysaccharide binding protein (LBP), wherein said effective amount of LBP binds to lipopolysaccharide (LPS) and suppresses septicemia caused by LPS.

E2 31. (Amended) The process of claim 28, wherein said LBP is at least one of rabbit or rat LBP.

32. (Amended) The process of claim 28, wherein said LBP is a hybrid of LBP and a lipopolysaccharide binding site of bacteriocidal/permeability increasing protein (BPI) or a hybrid of LBP and a lipopolysaccharide binding site of limulus anti-lipopolysaccharide factor (LALF).

33. (Amended) The process of claim 28, wherein said LBP comprises one or more point mutations which increases the binding affinity of LBP for lipopolysaccharide.